Versa Transcatheter Tricuspid Valve Repair System
Severe Tricuspid Regurgitation
Pre-clinicalActive
Key Facts
About Versa Vascular
Versa Vascular is an emerging player in the structural heart space, targeting the large and underserved market of tricuspid regurgitation (TR). The company is developing a catheter-based implant and delivery system that sits in the right atrium, aiming for a procedure that is stable, precise, and repositionable. Backed by a $27.3M Series C round and led by a team with deep structural heart expertise, Versa operates from the Occam Labs incubator ecosystem, positioning itself to advance its technology through development and toward clinical trials.
View full company profileTherapeutic Areas
Other Severe Tricuspid Regurgitation Drugs
| Drug | Company | Phase |
|---|---|---|
| TricValve | Relisys Medical Devices | Phase 2/3 |
| DUO System | CroiValve | Pre-clinical |
| Trisol Valve | Trisol Medical | Preclinical |
| EVOQUE Tricuspid Valve Replacement System | Edwards Lifesciences | Pivotal |